Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2011Expert Review of Hematology

Eltrombopag for the treatment of immune thrombocytopenia

View Full Paper
Ask AI
Bookmark
Share

Authors

GCGregory ChengSynertech PM (United States)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Gregory Cheng (2011) studied this question.

synapsesocial.com/papers/6a2058cf9cec6435c398f59dhttps://doi.org/10.1586/ehm.11.25
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP2008 · 436 citations
  2. 2Thrombopoietin Administered During Induction Chemotherapy to Patients With Acute Myeloid Leukemia Induces Transient Morphologic Changes That May Resemble Chronic Myeloproliferative Disorders2002 · 68 citations
  3. 3Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic Purpura2007 · 815 citations
  4. 4Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study2008 · 245 citations
  5. 5Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group2008 · 2,712 citations